An exciting drug-free treatment for ADHD

Neurode

Start-up medical device company Neurode is accessing the Federal Government’s flagship innovation program, the R&D Tax Incentive (‘RDTI’), to improve quality of life for people diagnosed with ADHD.

The Client

Using their background in brain machine interfaces, Neurode’s founders have been developing a drug-free solution to help patients diagnosed with ADHD and their treatment professionals.

The company has designed a headset that uses non-invasive electrical stimulation to balance brain activity and common symptoms of the disease. The system also provides a method to easily monitor symptoms and improvements and allow patients to share results with clinicians.

As the development and regulatory path for medical devices can be a long one, Neurode was open to various sources of funding to support the project including equity investment, grant funding and other financial resources.

The Solution

After consultation with Intellect Labs, it became clear that the RDTI would be an important part of Neurode’s go forward strategy. We worked with Neurode from the beginning of the RDTI process to discuss various early-stage development costs, provide advice on eligibility, and prepare an application form to advocate the project and it’s fit for the program.

Working with Intellect Labs from an early stage allowed Neurode to accurately project the size of the benefit that would be received from the RDTI, and the impact it would have on their cashflow and financial projections.

The Result

Neurode received a cash benefit from the R&D Tax Incentive which will be applied to further develop and commercialise the product.

As the program is run on an annual basis, Neurode is equipped to build the funding into their go forward innovation and funding strategy.